Tautomycetin
目录号 : GC11381Tautomycetin 是一种有效的特异性 PP1 抑制剂，具有潜在的细胞凋亡诱导活性。
Cas No.:119757-73-2
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
| Cell experiment [1]: | |
|
Cell lines |
Human primary T cells |
|
Preparation method |
The solubility of this compound in DMSO is >10 mM. General tips for obtaining a higher concentration: Please warm the tube at 37℃ for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below -20℃ for several months. |
|
Reacting condition |
1 μg/ml for 5 h |
|
Applications |
Tautomycetin possesses immunosuppressive activity to inhibit the proliferation of T cells by inhibition of IL-2 secretion. |
| Animal experiment [1]: | |
|
Animal models |
Rats after heterotopic cardiac transplantation |
|
Dosage form |
0.05 mg/kg. Tautomycetin solubilized in PBS or in microemulsion form for 30 days after heterocardiac transplantation. |
|
Application |
Immunosuppressive activity of tautomycetin is effective in an in vivo organ transplantation model (rats after heterotopic cardiac transplantation). |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1] Jae-Hyuck Shim, et al. Immunosuppressive effects of tautomycetin in vivo and in vitro via T cell-specific apoptosis induction. Proc Natl Acad Sci U S A. 2002 Aug 6; 99(16): 10617–10622. |
|
| Cas No. | 119757-73-2 | SDF | |
| 化学名 | (S)-(2S,3S,4R,7S,8R,11R,13R,Z)-17-ethyl-4,8-dihydroxy-3,7,11,13-tetramethyl-6,15-dioxononadeca-16,18-dien-2-yl 3-hydroxy-3-(4-methyl-2,5-dioxo-2,5-dihydrofuran-3-yl)propanoate | ||
| Canonical SMILES | O[C@@H]([C@H](C)C(C[C@H]([C@H](C)[C@H](C)OC(C[C@@H](C1=C(C)C(OC1=O)=O)O)=O)O)=O)CC[C@@H](C)C[C@@H](C)CC(/C=C(C=C)/CC)=O | ||
| 分子式 | C33H50O10 | 分子量 | 606.75 |
| 溶解度 | Soluble in DMSO (supplied pre-dissolved in DMSO, 10mg/ml) | 储存条件 | Desiccate at -20°C,protect from light |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 1.6481 mL | 8.2406 mL | 16.4813 mL |
| 5 mM | 0.3296 mL | 1.6481 mL | 3.2963 mL |
| 10 mM | 0.1648 mL | 0.8241 mL | 1.6481 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。